Constanze Jonak
Overview
Explore the profile of Constanze Jonak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
374
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chennareddy S, Rindler K, Meledathu S, Naidu M, Alkon N, Ruggiero J, et al.
J Allergy Clin Immunol
. 2024 Dec;
155(3):892-908.
PMID: 39694280
Background: Chronic erythroderma is a potentially life-threatening condition that can be caused by various diseases, but approximately 30% of cases remain idiopathic, often with insufficient treatment options. Objective: We sought...
2.
Li R, Strobl J, Poyner E, Balbaa A, Torabi F, Mazin P, et al.
Nat Immunol
. 2024 Dec;
26(1):147.
PMID: 39622949
No abstract available.
3.
Li R, Strobl J, Poyner E, Balbaa A, Torabi F, Mazin P, et al.
Nat Immunol
. 2024 Nov;
25(12):2320-2330.
PMID: 39558094
Cutaneous T cell lymphoma (CTCL) is a potentially fatal clonal malignancy of T cells primarily affecting the skin. The most common form of CTCL, mycosis fungoides, can be difficult to...
4.
Alkon N, Chennareddy S, Cohenour E, Ruggiero J, Stingl G, Bangert C, et al.
J Allergy Clin Immunol
. 2024 Sep;
155(2):461-478.
PMID: 39278361
Background: Mycosis fungoides (MF), the most common cutaneous T-cell lymphoma, is often underdiagnosed in early stages because of similarities with benign dermatoses such as atopic dermatitis (AD). Furthermore, the delineation...
5.
Chennareddy S, Rindler K, Ruggiero J, Alkon N, Cohenour E, Tran S, et al.
Br J Dermatol
. 2024 Aug;
192(2):269-282.
PMID: 39133553
Background: Malignant clones of primary cutaneous T-cell lymphomas (CTCL) can show a CD4+, CD8+ or T-cell receptor (TCR)-γδ+ phenotype, but their individual impact on tumour biology and skin lesion formation...
6.
Mitsunaga K, Bagot M, Ram-Wolff C, Guenova E, von Gugelberg C, Hodak E, et al.
Br J Dermatol
. 2024 Apr;
191(3):419-427.
PMID: 38596857
Background: Mycosis fungoides (MF) and Sézary syndrome (SS) are chronic malignant diseases that typically necessitate diverse strategies to achieve remission. Systemic interferon (IFN)-α (subtypes 2a and 2b) has been used...
7.
Blanchard M, Morren M, Busschots A, Hauben E, Alberti-Violetti S, Berti E, et al.
Br J Dermatol
. 2024 Apr;
191(2):233-242.
PMID: 38595050
Background: Lymphomatoid papulosis (LyP) is a rare cutaneous T-cell lymphoproliferative disorder. Comprehensive data on LyP in the paediatric population are scarce. Objectives: To characterize the epidemiological, clinical, histopathological and prognostic...
8.
Bangert C, Alkon N, Chennareddy S, Arnoldner T, Levine J, Pilz M, et al.
Nat Commun
. 2024 Apr;
15(1):2839.
PMID: 38565563
Dupilumab, an IL4R-blocking antibody, has shown clinical efficacy for atopic dermatitis (AD) treatment. In addition to conjunctivitis/blepharitis, the de novo appearance of head/neck dermatitis is now recognized as a distinct...
9.
Tittes J, Brell J, Fritz P, Jonak C, Stary G, Ressler J, et al.
Dermatol Ther (Heidelb)
. 2024 Mar;
14(3):613-626.
PMID: 38459237
Introduction: Targeting of the proinflammatory cytokine interleukin 17A (IL-17A) or tumor necrosis factor alpha (TNFα) with the monoclonal antibodies (mAbs) ixekizumab or adalimumab, respectively, is a successful therapy for chronic...
10.
Porkert S, Griss J, Hudelist-Venz M, Steiner I, Valencak J, Weninger W, et al.
J Dtsch Dermatol Ges
. 2024 Mar;
22(4):532-550.
PMID: 38444271
Background And Objectives: Mycosis fungoides (MF), the most common primary cutaneous T-cell lymphoma, is characterized by a variable clinical course, presenting either as indolent disease or showing fatal progression due...